Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review
{{output}}
Immune checkpoint inhibitors (ICIs) have increased modern anticancer armamentarium portfolios, with 15%-60% of cancer patients deriving clinical benefit while others progress, including some occurrences of accelerated progressions. ICIs have also introduced a ... ...